Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers

• Main Authors: Dekhnich A.V., Zubareva N.A., Kozlov R.S., Popov D.A., Romanov A.V., Rudnov V.A.
• Format: Article
• Language: Russian
• Published: Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy 2015-05-01
• Series: Клиническая микробиология и антимикробная химиотерапия
• Subjects: telavancin; glycopeptides; mrsa; skin and soft tissue infections; nosocomial pneumonia; bloodstream infections
• Online Access: https://cmac-journal.ru/publication/2015/2/cmac-2015-t17-n2-p127/cmac-2015-t17-n2-p127.pdf

Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) microorganisms, including multiresistant strains. Another perspective area of telavancin use — bloodstream infections, such as bacteremia and endocarditis. Telavancin is in vitro active against broad range of Gram(+) aerobic and anaerobic bacteria, including strains resistant to other antimicrobials: MRSA, MRSE, VISA, daptomycin non-susceptible strains of S. aureus, penicillin-resistant S. pneumoniae, ampicillin-resistant enterococci and enterococci with VanB phenotype of resistance to vancomycin. Talavancin is rapidly bactericidal due to its dual mechanism of action; it is active against intracellular bacterial cells and biofilmforming cells. Article reviews data of current in vitro and in vivo studies of telavancin, as well as clinical trials results.